Your browser doesn't support javascript.
loading
Clinical evidence and insights supporting the use of avelumab first-line maintenance treatment in patients with advanced urothelial carcinoma in the Asia-Pacific region.
Eto, Masatoshi; Lee, Jae-Lyun; Chang, Yen-Hwa; Gao, Seasea; Singh, Manmohan; Gurney, Howard.
Affiliation
  • Eto M; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Lee JL; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Chang YH; Taipei Veterans General Hospital, Taipei, Taiwan.
  • Gao S; Merck Pte. Ltd., Singapore, an affiliate of Merck KGaA.
  • Singh M; Pfizer Corporation Hong Kong Ltd., Hong Kong.
  • Gurney H; Department of Clinical Medicine, Macquarie University, Sydney, New South Wales, Australia.
Asia Pac J Clin Oncol ; 18(5): e191-e203, 2022 Oct.
Article in En | MEDLINE | ID: mdl-35238147
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Carcinoma, Transitional Cell / Antibodies, Monoclonal, Humanized Type of study: Guideline Limits: Humans Language: En Journal: Asia Pac J Clin Oncol Journal subject: NEOPLASIAS Year: 2022 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Carcinoma, Transitional Cell / Antibodies, Monoclonal, Humanized Type of study: Guideline Limits: Humans Language: En Journal: Asia Pac J Clin Oncol Journal subject: NEOPLASIAS Year: 2022 Document type: Article Affiliation country: Country of publication: